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Nicotine nasal spray with nicotine patch for smoking
cessation: randomised trial with six year follow up
Thorsteinn Blondal, Larus Jon Gudmundsson, Ingileif Olafsdottir, Gunnar Gustavsson, Ake Westin
Abstract
Objective To evaluate the efficacy of using a nicotine
patch for 5 months with a nicotine nasal spray for 1
year.
Design Placebo controlled, double blind trial.
Setting Reykjavik health centre.
Subjects 237 smokers aged 22›66 years living in or
around Reykjavik.
Interventions Nicotine patch for 5 months with
nicotine nasal spray for 1 year (n = 118) or nicotine
patch with placebo spray (n = 119). Treatment with
patches included 15 mg of nicotine for 3 months,
10 mg for the fourth month, and 5 mg for the fifth
month, whereas nicotine in the nasal spray was
available for up to 1 year. Both groups received
supportive treatment.
Main outcome measure Sustained abstinence from
smoking.
Results The log rank test for 6 years (÷2 = 8.5,
P = 0.004) shows a significant association between
abstinence from smoking and type of treatment.
Sustained abstinence rates for the patch and nasal
spray group and patch only group were 51% v 35%
after 6 weeks (P = 0.011 (÷2), 95% confidence interval
1.17% to 3.32%), 37% v 25% after 3 months
(P = 0.045, 1.01% to 3.08%), 31% v 16% after 6
months (P = 0.005, 1.27% to 4.50%), 27% v 11% after
12 months (P = 0.001, 1.50% to 6.14%), and 16% v 9%
after 6 years (P = 0.077, 0.93% to 4.72%).
Conclusions Short and long term abstinence rates
show that the combination of using a nicotine patch
for 5 months with a nicotine nasal spray for 1 year is a
more effective method of stopping smoking than
using a patch only. The low percentage of participants
using the nasal spray at 1 year, and the few relapses
during the second year, suggest that it is not cost
effective to use a nasal spray for longer than 7 months
after stopping a patch.
Introduction
In controlled clinical trials of nicotine replacement
therapy, 1 in 5 smokers remained abstinent after 1 year
compared with 1 in 10 smokers who abstained in self
administered cessation.1 Better treatments for smoking
cessation are clearly needed. In several controlled stud›
ies, the value of treatment with nicotine only has been
proved,2–4 but recent studies assessing the efficacy of
treatment with nicotine by high dose nicotine patches
gave different results.5–7 In the Collaborative European
Antismoking Evaluation study, evidence in favour of
dose›response relations was found, but increasing the
duration of patch use did not improve abstinence
rates.7 Few studies on smoking cessation have looked at
the effect of combining two or more methods of
providing nicotine, but those that are available seem to
suggest a higher efficacy through using more or differ›
ent ways of providing nicotine.8–10
The long term results of nicotine replacement
therapy have not been studied extensively. One recent
follow up study of a large multicentre trial on nicotine
patches reported abstinence rates of up to 20% for 4
years in the patch group versus 7% in the placebo
group.11 12 The respective abstinence rates for 1 year
were 29% and 10%. In another study, the abstinence
rates for patch and placebo for 3 years were 10% and
3% respectively.13 In a recently published study on nico›
tine nasal spray, the sustained abstinence rates for 3.5
years were 15% for the nasal spray and 6% for placebo.14
We evaluated the efficacy of using a nicotine patch
for 5 months with a nicotine nasal spray for 1 year on
smoking cessation. We studied the effects of a higher
level of nicotine substitution thus obtained and of
using a flexible method of providing nicotine with the
fixed method of a patch. We followed up the
participants after 6 years to assess the rates of
abstinence from smoking after the prescription for
nicotine had stopped.
Subjects and methods
Protocol
In November 1991 we started recruiting smokers from
Reykjavik and the surrounding towns (total population
about 150 000; smoking prevalence 34%) by advertise›
ments in local papers and on television. We evaluated
all respondents by interview at the baseline assessment.
To be eligible for the study, respondents had to be aged
21›69 years and had to have smoked at least one ciga›
rette per day for >3 years. We excluded those with a
history of recent myocardial infarction, severe nasal
allergy, or skin disease, and those who used smokeless
tobacco, were currently misusing alcohol, or were
pregnant or breast feeding.
We arranged contact with the participants on 10
occasions during the study and an additional follow up
after 6 years. The first contact was the baseline
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assessment conducted 3›6 weeks before the partici›
pants were to stop smoking. This appointment was fol›
lowed by an instructional meeting one day before the
participants were to stop smoking. We divided the 239
participants into 12 heterogeneous subgroups of
17›25 subjects each. The participants in each subgroup
were allocated either patch and nasal spray or patch
and placebo spray. The participants attended four sup›
portive group meetings 1, 8, 15, and 22 days after stop›
ping smoking. All participants were scheduled for
individual follow up at 6 weeks, and at 3, 6, 12, and 72
months. No participants were lost to follow up during
the first year; those who relapsed, however, were
contacted only by telephone at the 1 year follow up.
After 6 years all participants who were abstinent at 1
year were contacted again by telephone. At that time
two participants had died of cancer—one in each treat›
ment group. Participants abstinent at the 6 year follow
up came to the clinic for measurement of carbon mon›
oxide concentrations.
The outcome measure was the duration of
sustained abstinence. Participants were considered to
be smokers if they had, after stopping smoking, taken a
single puff of a cigarette, used other forms of tobacco,
used a nicotine drug other than that prescribed, had a
carbon monoxide concentration of >10 ppm, or were
lost to follow up. No participants were classified as
smokers solely on the basis of the non›attendance part
of the smoking status criteria—that is, no subject was
lost at any follow up. The time to relapse was calculated
as the number of days from stopping smoking to the
day of starting smoking. Carbon monoxide concentra›
tions were measured at baseline and at all subsequent
contacts, including follow up at 6 years, with a EC50
monitor (Bedfont Technical Instruments, Sittingborne,
Kent).
Statistical analyses
We based the number of participants required for the
efficacy analysis on a significance level of 5% using a
one tailed test, a power of 90%, and there being 55% of
participants in the patch and nasal spray group and
35% in the patch and placebo group; 105 participants
were needed in each treatment group. To allow for
withdrawals and protocol violations, however, we
aimed to analyse 120 participants. We used two sided
probability tests in all comparisons for more conclusive
results, and we considered a P value of < 0.05 as
significant. All tests were performed with spss
software.15
We used the ÷2 statistic to compare the proportions
of abstainers in both groups at the various follow up
times. To calculate the proportion of participants
remaining abstinent over time, we compared the
survival of the two groups using the Kaplan›Meier
method. Whenever distribution of data made it
possible, we carried out comparisons of continuous
variables between the groups using parametrical t tests,
and we used the Mann›Whitney rank sum test for data
that were non›normally distributed.
Assignment
On the day before the participants were due to stop
smoking, they were allocated their treatment by
computer generated randomisation code at a local
pharmacy. The nasal sprays—nicotine or placebo—
were taken from boxes labelled A or B, but the bottles
themselves were unlabelled. The pharmacy staff were
blinded to the content of the bottles. To prevent switch›
ing of treatments among participants and to help pro›
tect blinding, the same treatment was on four separate
occasions dispensed to four couples. The staff of the
smoking clinic had no knowledge of the treatment
assigned to each participant. A total of 239 subjects
were randomised. Two subjects were excluded early in
the trial without breaking the randomisation code.
They had been assigned the patch and nicotine spray.
One was unable to attend meetings because of illness,
and the other refused to use the drugs and attend
meetings, thus leaving a total of 237 participants.
Masking
Nasal sprays were dispensed in identical brown bottles
containing a colourless solution of either nicotine or
black pepper oleo resin (piperine). The nicotine spray
delivered 0.5 mg of drug per dose. The randomisation
code was kept at the pharmacy during the trial and not
broken until the data entry and analysis were
completed. Blinding among participants was success›
ful. At the 1 year follow up we found no significant
relation between type of treatment and the partici›
pants’ responses, which proved they had been unable
to guess their treatment. From previous experience,
one of the authors (TB) knew beforehand that partici›
pants using nasal spray for more than 3›6 months were
more likely to have been assigned the nicotine nasal
spray rather than placebo nasal spray.
Results
Table 1 shows the baseline characteristics of the
participants, and figure 1 illustrates the flow of the par›
ticipants through the trial.
Figure 2 shows the results of a Kaplan›Meier
survival analysis for 6 years with the proportion of par›
ticipants abstinent from smoking as the survival
variable. The results of the log rank test (÷2 = 8.5,
P = 0.004) show a significant association between absti›
nence and type of treatment. Table 2 shows the
percentage of participants abstinent from smoking at
the various follow up times. After 6 years, 1 out of 6
participants was still abstinent in the treatment group
compared with 1 out of 12 in the patch only group.
During the second year after the start of the study,
one participant relapsed in the patch only group and
three in the treatment group. During the next 4 years
Table 1 Baseline characteristics of participants. Values are mean (SD) unless stated
otherwise
Variables
Patch and nicotine spray
(n=118)
Patch and placebo spray
(n=119)
No of men 43 35
No of women 75 84
Mean age (years) (range) 41 (23›62) 43 (22›66)
Tobacco (g/day) 25.6 (15.7) 25.0 (10.9)
Mean Fagerstrom test of nicotine
dependence (1›10)
5.7 5.7
Mean cotinine concentration (ng/ml) (range) 378 (107›1138) 341 (37›765)
Carbon monoxide (ppm) 24.6 (12.30) 24.7 (10.70)
Mean body weight (kg) (range) 72 (40›119) 71 (48›118)
No of participants with history of treatment
for alcoholism (%)
19 (16.1) 22 (18.5)
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one participant relapsed and one died in the patch
only group, and nine relapsed and one died in the
treatment group.
Table 3 shows the proportion of participants using
the spray among those still abstinent at the various fol›
low up times, and the number of doses used in the
treatment group and patch only group. Participants
assigned the placebo spray used fewer doses and
stopped taking the spray earlier than those assigned
the nicotine nasal spray. At the 5 year follow up, 2 out
of 22 (9.1%) participants in the treatment group were
using nicotine chewing gum occasionally.
For the first 3 months, 91% or more of abstinent
participants in either group used patches. During the
following 2 months the participants discontinued
patch use successively, and after 5 months the
proportion was 25% to 30%. During the first 3 months
only, the mean number of patches containing 15 mg of
nicotine used by abstinent participants was signifi›
cantly greater in the patch only group (P = 0.038) than
in the treatment group.
Table 4 shows the level of substitution. In the treat›
ment group the level of substitution ranged from 45%
to 60% for the first 3 months versus 26% to 50% in the
patch only group. Four participants with higher than
average cotinine substititution concentrations (com›
pared with mean blood concentrations at baseline)
were still using nicotine nasal spray after 12 months. Of
those four, one relapsed during the second year and
two during the third year; the fourth participant
remained abstinent throughout the study.
At the various follow up times during the first 3
months, the incidence of side effects (a yes or no
answer) from patches ranged from 7% to 25% and
were most often graded as mild on a scale from mild
to moderate to severe. The most common side effects
were itchiness and skin irritation. At the various follow
up times during the first 3 months, the incidence of
side effects from nicotine nasal spray ranged from
5% to 25% and were most often graded as mild or
Registered patients meeting entry criteria (n=239)
Patch and nicotine
spray (n=120)
Followed up for 1 year
(n=118)
Excluded
Non-compliance (n=1)
Illness (n=1)
Patch and placebo
spray (n=119)
Followed up for 1 year
(n=119)
Randomised (n=239)
Death during observation
period (n=1)
Death during observation
period (n=1)
Followed up for 6 years
(n=117)
Followed up for 6 years
(n=118)
Completed trial
(n=117)
Completed trial
(n=118)
Clinic visit of participants
abstinent at 6 year follow up
(n=19)
Clinic visit of participants
abstinent at 6 year follow up
(n=10)
Fig 1 Flow of participants through trial
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Fig 2 Kaplan›Meier survival curves showing difference in abstinence
rates between participants allocated nicotine patch and nicotine nasal
spray and those allocated nicotine patch only. Number of relapses
during the 5 years was 12 v 2 in the treatment and patch only
groups respectively (two abstinent participants died during the 6
year follow up period; one in each treatment group)
Table 2 Percentage (number) of participants abstinent from smoking at follow up
Follow up
Patch and nicotine
spray (n=118)
Patch and placebo
spray (n=119) P value (÷2) Odds ratio (95% CI)
1 day 88.1 (104) 82.4 (98) 0.210 1.59 (0.77 to 3.30)
15 days 70.3 (83) 52.1 (62) 0.004 2.18 (1.28 to 3.72)
43 days 50.8 (60) 34.5 (41) 0.011 1.97 (1.17 to 3.32)
3 months 37.3 (44) 25.2 (30) 0.045 1.76 (1.01 to 3.08)
6 months 31.4 (37) 16.0 (19) 0.005 2.40 (1.27 to 4.50)
1 year 27.1 (32) 10.9 (13) 0.001 3.03 (1.50 to 6.14)
6 years* 16.2 (19) 8.5 (10) 0.08 2.09 (0.93 to 4.72)
*Two subjects died, one in each treatment group, between 1 and 6 years of follow up: percentages
calculated as 19/117 in treatment group and 10/118 in patch only group.
Table 3 Number of smokers abstaining at each follow up and percentage of abstainers
using spray. Doses of self reported nasal spray (1 mg)
Period
Patch and nicotine
spray (n=118) Mean (SD)
Patch and placebo
spray (n=119) Mean (SD)
1 day 104 (89) 10 (6) 98 (92) 11 (7)
15 days 83 (77) 11 (7) 62 (68) 9 (6)
22 days 75 (64) 10 (7) 57 (54) 7 (6)
43 days 60 (52) 11 (7) 41 (39) 6 (5)
3 months 44 (39) 11 (8) 30 (20) 4 (1)
4 months 44 (23) 17 (9) 30 (3) 5 (0)
5 months 40 (28) 16 (9) 24 (4) 5 (0)
6 months 37 (24) 14 (9) 19 (5) 5 (0)
12 months 32 (13) 22 (9) 13 (0) —
Table 4 Cotinine substitution concentrations
Period
Patch and nicotine spray Patch and placebo spray
Users* Mean
% of baseline
cotinine† Users* Mean
% of baseline
cotinine†
Baseline 111 378 100 111 341 100
1 day 94 227 60.1 90 170 49.9
15 days 61 171 45.2 56 128 37.5
43 days 31 192 50.8 38 136 39.9
3 months 16 191 50.5 27 88 25.8
6 months 8 226 59.8 0 0 0
12 months 4 495 131 0 0 0
*Those abstinent in respective treatment groups and using prescribed nicotine as either patch with nicotine
nasal spray or patch only. At baseline, users refers to smokers.
†Percentages at each follow up derived from mean cotinine concentration at baseline.
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moderate, but at follow up on day 1 after stopping
smoking, 7 out of 22 participants with side effects
graded theirs as severe. The most common side effect
was nasal irritation.
Discussion
Our study shows that from day 15 after stopping
smoking the use of a nicotine patch with a nicotine
nasal spray is significantly more effective at stopping
smoking than using a nicotine patch with placebo
spray (fig 1, table 2). The difference in abstinence rates
was double at 6 months and triple at 1 year, and after
a further 5 years without nicotine replacement
therapy the difference between treatment groups was
double.
The participants in the treatment group had
received an incentive over the patch only group by hav›
ing access to nicotine nasal spray during the first year,
thus alleviating smoking urges and giving them time to
consider changes in self image. The almost triple differ›
ence in abstinence rates after 1 year (P = 0.001) can
probably be explained by higher levels of substitution
during the first 5 months (table 4), and particularly so
during the remaining 7 months when only the
treatment group had access to the nictoine spray, even
if the spray was not always used daily (table 3).
The results suggest an increased efficacy in preven›
tion of relapse with more intake of nicotine or by com›
bining different nicotine replacement therapies.8–12
Whether the quantitative or the qualitative aspect is
more decisive can not be decided from the design of
our study. Studies on dose›response relations of
nicotine substitution have given different results.7 16–18
The combination of a nicotine patch and nicotine
nasal spray may have been successful not only because
of the high level of substitution (table 4) but also
because of the opportunity to respond quickly to the
smoker’s need.
Within the treatment group, 32 of the 118
participants (27%) were abstinent from smoking at 1
year and only 4 out of 32 were still using the nicotine
nasal spray at that time. These four were, however,
using high doses of nicotine throughout the study.
The 6 year abstinence rate in the treatment group
was 16% versus 9% in the patch only group, a finding
that shows the long term efficacy of treatment.
In one study of nicotine patches, continuous self
reported abstinence rate at 4 years follow up was 20%
for a patch with 21 mg of nicotine, 7% for placebo, and
intermediate for patches with 14 mg and 7 mg of nico›
tine.11 Our study confirms that by providing nicotine in
several combinations, abstinence rates at 6 years can be
double those of using a single method of nicotine
replacement. It must still be acknowledged, however,
that 7 out of 10 smokers relapse within the first year of
stopping smoking.
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Key messages
x Combined methods of nicotine replacement
therapy have a potential advantage over one
method because of high levels of substitution
x Nicotine patches release nicotine slowly, but
nicotine nasal spray delivers nicotine more
rapidly, enabling the smoker to respond quickly
to any smoking urges
x Treatment with a patch and nicotine nasal
spray was significantly more effective than
patch and placebo from day 15 after stopping
smoking
x Using a patch for 5 months with a nicotine
nasal spray for 1 year provides a more effective
means of stopping smoking than using a patch
only
x It is not cost effective to use a nicotine nasal
spray for longer than 7 months after stopping a
patch
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Commentary: Progress on nicotine replacement therapy for
smokers
John Stapleton
Four preparations for nicotine replacement therapy—
chewing gum, skin patch, nasal spray, and buccal
inhalator—have each been shown to approximately
double a person’s chance of stopping smoking.1
Success rates are modest, however, with typically about
10›30% of smokers continuously abstinent for 1 year,
depending on the quantity and quality of behavioural
or counselling support.
One reason why success rates with nicotine
replacement therapy are not higher is that no current
formulation mimics the extremely rapid, rewarding,
high arterial nicotine concentrations from inhaled
tobacco smoke. A second possible explanation is
underdosing. When used in standard doses all the
products tend to give trough plasma nicotine concen›
trations, which are less than half of those a moderate to
heavy smoker is accustomed to from cigarettes.
Nicotine from the skin patch is absorbed into the
bloodstream at a slow but steady rate throughout the
day. The user has no control over dosing, but the patch
is easy to use and ensures high compliance and reliable
nicotine concentrations from the first day of use.
Underdosing is mainly because the patch delivers less
nicotine than smokers obtain during the daytime from
cigarettes. Dosing with the nicotine chewing gum, nasal
spray, and buccal inhalator is under the control of the
user. Like smoking, their use includes some behav›
ioural activity and provides sensory stimulation. They
allow users to adjust the dose of nicotine as needed,
albeit with less control and much more slowly than
with cigarettes. Underdosing with these products is
mainly because smokers cannot master the correct
technique for their use, or because they find the irritant
side effects unpleasant.
So far, results from studies of single preparations
with increased nicotine doses have been disappointing.
The only published large trial to examine the effect of
doubling the patch dose (from 21 mg of nicotine per
24 hours to 42 mg per 24 hours) showed only a small
transient benefit on smoking cessation over the stand›
ard dose.2 Also, increasing the dose of nicotine in gum
(from 2 mg to 4 mg per piece) has not proved univer›
sally advantageous in trials, although there is evidence
of an additional benefit for more dependent smokers.3
Results from studies of the combined use of patch
and gum seem to offer more promise. Two placebo
controlled trials have been published, one showing an
advantage of using the combined treatment over patch
alone, the other over gum alone.4 5 Blondal and
colleagues’ article reports on the first trial of a nicotine
patch with nicotine nasal spray in smoking cessation.
The combination produced nicotine replacement con›
centrations exceeding 50% of trough smoking concen›
trations, and was more than twice as effective as a patch
with placebo spray. Pooling the results of the new study
with those from the other combination trials gives an
odds ratio of 12 month cessation for combination ver›
sus single treatment of 1.8 (95% confidence interval 1.2
to 2.8), that is, an improvement approximately equal to
that for any single product for nicotine replacement
therapy over placebo.
The new study is exceptional in following patients
for 6 years and so provides much needed data on long
term abstinence rates, and therefore the health benefits
and cost effectiveness of a single course of nicotine
replacement therapy.6 There was still a clear advantage
for the combination treatment after 6 years, with twice
the number of successes, but 35% of abstainers at 1
year had relapsed by this time and the number needed
to treat for each additional success with the
combination consequently increased from 6 to 13. The
nicotine nasal spray was used for up to 1 year in the
trial, whereas the patch was phased out after 3 months.
Since 57% of patients in the patch only group
compared with 32% in the combination group
relapsed between 3 months and 1 year, the extended
period of spray use was clearly beneficial in preventing
relapse during this period.
We cannot tell from this study how much of the
success of the combined treatment was due to it
providing higher concentrations of nicotine replace›
ment, and how much was due to the flexible mode of
delivery. The inclusion of a higher dose patch might
have enlightened us, but such a design would have
required a far larger study. Taken with evidence from
other studies, however, this study supports the notion
that higher concentrations of nicotine replacement are
beneficial if they are achieved through allowing a
degree of individual control over dosing, together with
a reliable, if passive, method of delivering nicotine.
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Endpiece
The difference
The consultant is distinguished from the general
practitioner less by the subtlety of his treatment
than by the strength of conviction with which he
executes it.
Thomas McKeown, The role of medicine. Dream,
mirage or nemesis? (1979)
Submitted by Nicholas Steel, health services research
fellow, University of East Anglia
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